Basking Biosciences is a clinical-stage biopharmaceutical company focused on developing a rapid-onset, short-acting thrombolytic drug for reopening blocked arteries, with the ability to quickly reverse its activity in case of bleeding complications. Their lead drug candidate, BB-031, utilizes RNA aptamer technology to target von Willebrand Factor, aiming to enhance safety and effectiveness in acute revascularization therapy.
Market
Acute thrombosis treatment
Location
Columbus,
Ohio,
USA
Coinvestors
ARCH Venture Partners, Insight Partners, Longview Ventures, Platanus, Rev1 Ventures, RTW Investments, Solas Bioventures, The Ohio State University